期刊
DRUG AND ALCOHOL DEPENDENCE
卷 138, 期 -, 页码 83-88出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2014.02.002
关键词
Addiction; Detoxification; Pharmacotherapy; Opioid agonist; Opioid antagonist; Minority recruitment
资金
- Alkermes, Inc.
- U.S. National Institutes of Health [U10DA013727, R33DA027503, R01DA019623, R01MD007658, U10 DA-13043, 1035 DA17009]
Background: The approval of extended release injectable naltrexone (XR-NTX; Vivitrol (R)) has introduced a new option for treating opioid addiction, but studies are needed to identify its place within the spectrum of available therapies. The absence of physiological opioid dependence is a necessary and challenging first step for starting XR-NTX. Outpatient detoxification gives poor results and inpatient detoxification is either unavailable or too brief for the physiological effects of opioids to resolve. Here we present findings from an open label study that tested whether the transition from opioid addiction to XR-NTX can be safely and effectively performed in an outpatient setting using very low dose naltrexone and buprenorphine. Methods: Twenty treatment seeking opioid addicted individuals were given increasing doses of naltrexone starting at 0.25 mg with decreasing doses of buprenorphine starting at 4 mg during a 7-day outpatient XR-NTX induction procedure. Withdrawal discomfort, craving, drug use, and adverse events were assessed daily until the XR-NTX injection, then weekly over the next month. Results: Fourteen of the 20 participants received XR-NTX and 13 completed weekly assessments. Withdrawal, craving, and opioid or other drug use were significantly lower during induction and after XR-NTX administration compared with baseline, and no serious adverse events were recorded. Conclusions: Outpatient transition to XR-NTX combining upward titration of very low dose naltrexone with downward titration of low dose buprenorphine was safe, well tolerated, and completed by most participants. Further studies with larger numbers of subjects are needed to see if this approach is useful for naltrexone induction. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据